ADMA Biologics, Inc. (ADMA) bonds
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3029% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$196.59M
$3.75M due within a year
Net debt
$60.57M
After $136.02M of cash
Implied interest rate
9.84%
FY2025 interest ÷ average debt
Interest coverage
26.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in ADMA Biologics's 10-K for the period ended Dec 31, 2025
ADMA Biologics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| JPM Term Loan | – | $74.06M |
See a number that looks wrong?